

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
02 November 2023 (02.11.2023)



(10) International Publication Number
WO 2023/212722 A1

(51) International Patent Classification:

C12N 5/078 (2010.01) C12N 15/113 (2010.01)
C12N 9/22 (2006.01) C12N 15/90 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/066396

(22) International Filing Date:

28 April 2023 (28.04.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/336,248 28 April 2022 (28.04.2022) US

(71) Applicant: **BLUEROCK THERAPEUTICS LP**
[US/US]; 238 Main Street, 3rd floor, Cambridge, MA 02142
(US).

(72) Inventors: **SOH, Chew-Li**; c/o BlueRock Therapeutics LP,
238 Main Street, 3rd floor, Cambridge, MA 02142 (US).
TOMISHIMA, Mark J.; c/o BlueRock Therapeutics LP,
238 Main Street, 3rd floor, Cambridge, MA 02142 (US).
MCAULIFFE, Conor B.; c/o BlueRock Therapeutics LP,
238 Main Street, 3rd floor, Cambridge, MA 02142 (US).
WILKINSON, JR., Dan Charles; c/o BlueRock Thera-
peutics LP, 238 Main Street, 3rd floor, Cambridge, MA
02142 (US). **BURNETT, Benjamin**; c/o BlueRock Ther-
apeutics LP, 238 Main Street, 3rd floor, Cambridge, MA
02142 (US).

(74) Agent: **BETTI, Christopher J.**; c/o Morgan, Lewis &
Bockius LLP, 110 N. Wacker Drive, 28th Floor, Chicago,
IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: NOVEL SITES FOR SAFE GENOMIC INTEGRATION AND METHODS OF USE THEREOF

(57) Abstract: The present disclosure is directed to genetically modified cells that express one or more transgenes at a sustained expression level from a site for safe genomic integration and stable expression. Also provided are methods of making the cells and nucleic acid vectors that can be used to make the cells.

WO 2023/212722 A1